ANTWERP, Belgium, February 9, 2026 (GLOBE NEWSWIRE) – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need, today announced the closing of its previously announced initial public offering of 12,500,000 American Depositary Shares (“ADSs”) representing 12,500,000 of its common shares, at a pu ...

ALISO VIEJO, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma”), a late-stage biopharmaceutical company, today announced the closing of its initial public offering of 10,781,250 shares of its common stock, which includes the exercise in full of the underwriters’ option to purchase 1,406,250 additional shares of its common stock, at a public offering price of $16.00 per share. The aggregate gross proceeds from the offering were $172.5 million, before deducting u ...

Core Insights - Praxis Precision Medicines, Inc. will report its financial results for Q4 and the full year ended December 31, 2025, on February 19, 2026, before the market opens [1] - The company will host a conference call and live webcast on the same day at 8:00 am ET to review the financial results and provide a corporate update [2] - Praxis has a diversified CNS portfolio with multiple programs across movement disorders and epilepsy, including four late-stage product candidates [4] Company Overview - Praxis Precision Medicines is a leading CNS precision neuroscience biopharmaceutical company focused on developing therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance [4] - The company utilizes its proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, to translate genetic insights into therapeutic development [4] - Praxis is actively participating in investor conferences, including the Guggenheim Emerging Outlook: Biotech Summit on February 11, 2026, and the TD Cowen 46th Annual Health Care Conference on March 2, 2026 [5]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Mereo BioPharma Group plc due to alleged violations of federal securities laws related to misleading statements about clinical trial results [2][4]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Mereo BioPharma to contact them to discuss their legal options [1]. - There is a deadline of April 6, 2026, for investors to seek the role of lead plaintiff in a federal securities class action against Mereo [2]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3]. Group 2: Clinical Trial Results - Mereo BioPharma announced on December 29, 2025, that two Phase 3 studies of setrusumab failed to meet their primary endpoints of reducing annualized clinical fracture rates compared to placebo and bisphosphonates [5]. - Despite the failure to meet primary endpoints, the trials showed statistically significant improvements in bone mineral density on secondary endpoints, and no new safety concerns were identified [5]. - Following the announcement, Mereo's stock price plummeted by $2.02 per share, or 87.64%, closing at $0.28 per share [6]. Group 3: Class Action Details - The lead plaintiff in a class action is defined as the investor with the largest financial interest who is adequate and typical of class members [7]. - Any member of the putative class can move the Court to serve as lead plaintiff or choose to remain an absent class member without affecting their ability to share in any recovery [7]. Group 4: Whistleblower Encouragement - Faruqi & Faruqi, LLP is also encouraging anyone with information regarding Mereo BioPharma's conduct, including whistleblowers and former employees, to contact the firm [8].

Core Insights - Zacks Premium offers various tools for investors to enhance their stock market engagement and confidence, including daily updates, research reports, and stock screens [1][2] Zacks Style Scores - Zacks Style Scores are indicators that rate stocks based on value, growth, and momentum characteristics, helping investors identify stocks likely to outperform the market in the short term [2][3] - Each stock receives a rating from A to F, with A indicating the highest potential for outperformance [3] Value Score - The Value Style Score identifies attractive stocks based on valuation ratios such as P/E, PEG, Price/Sales, and Price/Cash Flow, appealing to value investors [3] Growth Score - The Growth Style Score focuses on a company's future prospects and financial health, analyzing projected and historical earnings, sales, and cash flow to find sustainable growth stocks [4] Momentum Score - The Momentum Style Score helps investors capitalize on price trends, using metrics like one-week price changes and monthly earnings estimate changes to identify optimal entry points [5] VGM Score - The VGM Score combines the three Style Scores, providing a comprehensive rating that highlights stocks with strong value, growth potential, and positive momentum [6] Zacks Rank - The Zacks Rank is a proprietary model that uses earnings estimate revisions to assist investors in building successful portfolios, with 1 (Strong Buy) stocks historically yielding an average annual return of +23.83% since 1988, outperforming the S&P 500 [7][8] - There are typically over 800 top-rated stocks available, making it essential for investors to utilize Style Scores for better selection [9] Stock to Watch: Incyte Corporation - Incyte Corporation, a biopharmaceutical company, is currently rated 3 (Hold) on the Zacks Rank and has a VGM Score of A, indicating solid potential [12] - The company has a Value Style Score of B, supported by a forward P/E ratio of 14, making it attractive to value investors [13] - Recent analyst revisions have increased earnings estimates for fiscal 2025, with the Zacks Consensus Estimate rising to $6.87 per share and an average earnings surprise of +14.4%, positioning Incyte as a noteworthy investment opportunity [13]

Core Insights - Biofrontera Inc. announced positive Phase 3 clinical trial results for Ameluz PDT, demonstrating significant efficacy in treating actinic keratoses (AKs) on various body areas [1][5][9] Study Design and Results - The Phase 3 study was a multicenter, randomized, double-blind, vehicle-controlled trial involving 172 patients, with a 4:1 randomization to receive Ameluz gel or vehicle gel [2] - The primary endpoint was the "subject complete clearance rate," defined as the percentage of patients achieving complete clearance of all treated AK lesions 12 weeks post-treatment [4] - Ameluz PDT showed a complete clearance rate of 45.6% in the Full Analysis Set (FAS) compared to 16.7% for vehicle PDT (p < 0.0003) [5] - In the Per Protocol Set (PPS), complete clearance rates were 53.2% for Ameluz PDT versus 22.2% for vehicle PDT (p < 0.001) [5] Secondary Outcomes - Key secondary outcomes indicated a 73.1% clearance rate of AK lesions in the FAS and 80.3% in the PPS 12 weeks after treatment [6] - Clearance rates by anatomical location showed 38.5% (FAS) and 46.5% (PPS) on extremities, and 74.1% (FAS) and 78.3% (PPS) on neck and trunk [6] Patient Satisfaction and Cosmetic Outcomes - Ameluz PDT demonstrated favorable cosmetic outcomes, with 75.2% of investigators rating treated skin as "good" or "very good" [7] - 70.9% of patients reported similar assessments, and 86.3% indicated they would choose PDT again for future treatment [7] Future Plans - Based on the positive results, Biofrontera plans to submit a supplemental New Drug Application (sNDA) to the U.S. FDA in Q3 2026 [8]

Company Overview - Palisade Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation, once-daily oral PDE4 inhibitor prodrugs aimed at targeted delivery to the terminal ileum and colon [2][6] - The company's lead program, PALI-2108, is designed to improve pharmacology, tolerability, and convenience for patients with inflammatory and fibrotic diseases [6][7] Product Details - PALI-2108 is a once-daily oral prodrug that is pharmacologically inactive until it reaches the lower intestine, where it is activated by bacterial enzymes at sites of inflammation and fibrosis [5][7] - In a recent Phase 1b trial, PALI-2108 achieved a 100% clinical response in the ulcerative colitis (UC) cohort, with no serious adverse events reported [7] - The company is advancing towards a Phase 2 clinical study in UC, which will evaluate clinical remission, response, and pharmacodynamic biomarkers over 12 weeks [8] Upcoming Events - JD Finley, CEO, and Dr. Mitchell Jones, President and CMO, will participate in a virtual fireside chat at the Piper Sandler Virtual Novel Targets in Immunology Symposium on February 12, 2026 [2][3] - A live webcast of the presentation will be available on the company's website, with a replay accessible for a limited time [4]

Core Insights - Entera Bio Ltd. has appointed Geno J. Germano as the new Chairman of the Board, effective February 4, 2026, succeeding Gerald Lieberman [1] - The company is advancing two oral PTH peptide programs into clinical testing in 2026, including a Phase 3 study for EB613 in osteoporosis and a first-in-human study for Long-Acting Oral PTH in hypoparathyroidism [2] Leadership Changes - Geno J. Germano brings over three decades of leadership experience in the pharmaceutical and life sciences sectors, having held senior roles at Pfizer, including Group President of Pfizer's Global Innovative Pharmaceutical Business, managing a portfolio worth approximately $14 billion [4] - The CEO of Entera, Miranda Toledano, expressed gratitude for the contributions of the outgoing Chairman and emphasized the importance of Germano's experience in scaling therapeutic platforms [3] Product Development - Entera's lead clinical asset, EB613, is positioned to transform osteoporosis treatment by providing an oral anabolic therapy, which could facilitate earlier intervention in treatment paradigms [3] - The company is also developing other oral peptide therapies, including EB612 for hypoparathyroidism and a dual-targeted GLP-1/glucagon peptide for obesity and metabolic syndromes [5]

Core Viewpoint - A class action lawsuit has been filed against Mereo BioPharma Group plc on behalf of investors who purchased Mereo American Depositary Shares during the specified Class Period, alleging misleading information regarding clinical study results [1][3]. Company Overview - Mereo BioPharma Group plc is a biopharmaceutical company headquartered in London, focusing on treatments for rare diseases [2]. Legal Action Details - The lawsuit claims that Mereo misled investors by raising expectations about the ORBIT and COSMIC studies for setrusumab, which did not significantly reduce clinical fracture rates compared to control groups [3]. - Following the disclosure of the study results, Mereo's ADS price fell dramatically from $2.31 on December 26, 2025, to $0.29 on December 29, 2025, resulting in a loss of over 87.7% of its value in one day [3]. Investor Information - Investors who purchased Mereo securities during the Class Period have until April 6, 2026, to seek appointment as a lead plaintiff representative of the class [2].

Core Viewpoint - Bristol-Myers Squibb Company (NYSE:BMY) is recognized as one of the 10 Most Profitable Undervalued Stocks to Buy, with multiple firms raising their price targets following positive earnings reports and promising pipeline developments [1][3][5]. Price Target Updates - Guggenheim raised its price target on BMY to $72 from $62, citing a significant increase in the estimated probability of success for key drugs [1]. - Bank of America increased its price target to $68 from $64, highlighting strong fourth-quarter results and positive fiscal 2026 guidance [3]. - Wells Fargo raised its price target to $60 from $55, indicating potential upside if the growth portfolio exceeds current expectations [4]. - Citi lifted its price target to $64 from $60, maintaining a Neutral rating while emphasizing the importance of pipeline execution for future share upside [5]. Financial Performance - Bristol-Myers reported fourth-quarter revenue of $12.5 billion, surpassing the consensus estimate of $12.28 billion, indicating strong performance and momentum in its growth portfolio [6]. Pipeline and Future Outlook - The company is expected to have a data-rich 2026, with multiple pivotal pipeline readouts anticipated in the latter half of the year, which could significantly impact its growth trajectory [6]. - Analysts noted that the positive Phase 3 read-across from Bayer's SSP data helps to mitigate risks associated with the milvexian opportunity [3].